Cancer Drug Shortages Persist as 96% of U.S. Centers Report Ongoing Supply Issues
Event summary
- 96% of leading U.S. cancer centers report persistent drug shortages, unchanged since 2023
- 94% of centers face ifosfamide shortages, 71% report carboplatin shortages
- 100% of centers report shortages of at least one anti-cancer agent
- 61% of centers implement pharmacy/physician-led mitigation strategies
- NCCN coalition proposes policy changes to address economic incentives for generic drug manufacturing
The big picture
The persistent shortages of critical cancer medications highlight systemic vulnerabilities in the generic drug supply chain. Despite years of advocacy, policy interventions have failed to address economic disincentives for manufacturers. This creates operational challenges for cancer centers, diverting resources from patient care to crisis management. The situation underscores broader healthcare delivery risks when essential treatments become economically unattractive to produce at scale.
What we're watching
- Regulatory Response
- Whether FDA will implement earlier notification requirements from manufacturers as requested by 96% of surveyed centers
- Policy Impact
- The pace at which economic incentives for generic drug manufacturing will be enacted through the End Cancer Drug Shortages Coalition's proposals
- Operational Strain
- How sustained shortages will affect cancer centers' ability to maintain clinical trial continuity and patient care standards
Related topics